• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Define Ventures Appoints Bruce Broussard as Venture Partner

    10/22/24 9:00:00 AM ET
    $EVH
    $HIMS
    $HUM
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care
    Get the next $EVH alert in real time by email

    The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation

    SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companies. 

    Bruce is a seasoned healthcare executive and multi-time CEO, having held executive leadership positions across multiple corners of the ecosystem. Prior to joining Define, Bruce was president and CEO of Humana for over a dozen years. Under his leadership, Bruce led a strategic shift towards expanding the company into an integrated model with a growing care delivery focus. Bruce also held several roles at McKesson Specialty Health including CEO, CFO, President, and Chairman of the Board. He currently serves on the Humana Foundation Board, is Chair of the Board of Directors of the Trust for the National Mall, and is a board member for HP Inc. and One Call.

    "Bruce's extensive background and proven track record in leading healthcare organizations of all sizes makes him uniquely qualified to guide the next generation of health tech innovators," said Lynne Chou O'Keefe, founder and managing partner at Define Ventures. "Having had the privilege to closely partner with Bruce for the past decade, I am confident his decision to join our team will sharpen our investing theses, accelerate our partner companies' growth, strengthen our relationships with large healthcare organizations, and ultimately create a lasting impact on the broader health tech community."

    Bruce is joining a team that pulls the full weight of its network and expertise to play offense and drive results, including securing early customers, shaping commercial strategies, and building high-performing teams. As venture partner, Bruce will leverage his experience driving transformative change within complex healthcare organizations to help Define founders to navigate industry challenges and scale their innovations effectively. His perspective will also strengthen Define's close partnerships with its coalition of large health systems, health plans, employers, and life sciences companies, half of which are customers of Define partner companies.

    "What excites me the most about this role is the opportunity to work with brilliant, innovative entrepreneurs at the earliest stages of their journey," Broussard said. "Being able to see groundbreaking approaches from the start, and having the chance to shape products and help scale and bring them to market is truly invigorating. Ultimately, I chose to work with Define because I believe this firm is uniquely positioned and capable of driving real transformation in healthcare. The strong, trustworthy relationship we've built over the years has shown me that Define's vision aligns perfectly with my own. Together, I believe we can make significant strides in creating a healthcare system that's more efficient, more accessible, and more focused on keeping people healthy."

    Bruce's decision to join Define Ventures stems from his belief that the firm is uniquely positioned and capable of transforming healthcare. He has built a strong and trustworthy relationship with Define over the past several years, including first-hand experience in incubating and spinning out Cohere Health from Humana. This collaborative history underscores the alignment between Bruce's vision for healthcare innovation and Define's strategic approach.

    Define Ventures has $800 million in assets under management and partners with companies at the seed, series A and series B stages. The firm attracts leading health tech entrepreneurs with its high conviction approach, partnering with over two dozen companies including Hims & Hers (NYSE:HIMS) and Unite Us. This announcement follows Frank Williams, co-founder and former CEO of Evolent (NYSE:EVH) joining Define as venture partner earlier this year.

    To learn more about Define Ventures, visit www.definevc.com.

    About Define Ventures

    Define Ventures is one of the largest funds focused on early-stage health tech companies. With $800 AUM, we take a high conviction approach in partnering with companies at the earliest stages. We believe the future of healthcare will be defined who bring together a deep understanding of the healthcare ecosystem paired with a technology-driven mindset. Our team was built in this vision, bringing together founders and investors who built category-defining companies and delivered $23 billion in exit value, including Livongo (LVGO), Evolent (NYSE:EVH), and Hims & Hers (NYSE:HIMS).

    Cision View original content:https://www.prnewswire.com/news-releases/define-ventures-appoints-bruce-broussard-as-venture-partner-302282546.html

    SOURCE Define Ventures

    Get the next $EVH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • Who has joined Define Ventures as a venture partner, and what is his background?

      Bruce Broussard, the former CEO of Humana, has joined Define Ventures as a venture partner to drive transformative change in healthcare and support early-stage health tech companies.

    • What is Define Ventures' focus and how much capital do they manage?

      Define Ventures focuses on early-stage health tech companies and has $800 million in assets under management (AUM). They partner with companies typically at the seed, series A, and series B stages.

    • Why has Bruce Broussard chosen to work with Define Ventures?

      Broussard believes Define Ventures is uniquely positioned to drive real transformation in healthcare, based on his strong relationship with the firm and shared vision for healthcare innovation.

    • What role will Bruce Broussard play at Define Ventures?

      Broussard will leverage his extensive experience in healthcare to guide founders through challenges, helping them scale their innovations and strengthen partnerships with large healthcare organizations.

    • Which companies has Define Ventures partnered with, showcasing their investment strategy?

      Define Ventures has partnered with notable companies in the health tech space, including Hims & Hers and Unite Us, highlighting their investment strategy focused on impactful entrepreneurs.

    Recent Analyst Ratings for
    $EVH
    $HIMS
    $HUM

    CompanyDatePrice TargetRatingAnalyst
    Humana Inc.
    $HUM
    5/1/2025$315.00Mkt Perform → Outperform
    Raymond James
    Hims & Hers Health Inc.
    $HIMS
    4/29/2025$30.00Buy → Hold
    TD Cowen
    Hims & Hers Health Inc.
    $HIMS
    2/18/2025$42.00 → $60.00Overweight → Equal-Weight
    Morgan Stanley
    Hims & Hers Health Inc.
    $HIMS
    1/10/2025$24.00 → $25.00Neutral → Sell
    Citigroup
    Evolent Health Inc
    $EVH
    1/10/2025$15.00Buy
    Needham
    Hims & Hers Health Inc.
    $HIMS
    1/7/2025$35.00Buy
    BTIG Research
    Hims & Hers Health Inc.
    $HIMS
    12/17/2024$42.00Overweight
    Morgan Stanley
    Evolent Health Inc
    $EVH
    12/3/2024$36.00 → $29.00Buy
    BTIG Research
    More analyst ratings

    $EVH
    $HIMS
    $HUM
    Financials

    Live finance-specific insights

    See more
    • Evolent Announces First Quarter 2025 Results

      WASHINGTON, May 8, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent Health kicked off 2025 with first quarter results at the high end of our expectations, and we are reiterating our outlook for full year 2025 revenue and Adjusted EBITDA. We continue to see a very strong selling environment and we achieved significant organic growth with five

      5/8/25 4:10:00 PM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results

      Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 million to $335 million Introduces 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2025, in a shareholder letter that is posted at investors.him

      5/5/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Humana Reports First Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted Financial Guidance

      Reports 1Q25 earnings per share (EPS) of $10.30 on a GAAP basis, Adjusted EPS of $11.58 1Q25 Insurance segment benefit ratio of 87.4 percent, in line with the company's previously disclosed expectation of 'approximately 87.5 percent' Affirms Adjusted FY 2025 EPS guidance of 'approximately $16.25'; while revising GAAP EPS to 'approximately $14.68' from the previous estimate of 'approximately $15.88' Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent Affirms expected individual Medicare Advantage annual membership decline of approximately 550,000, inclusive of the impact of exiting certain unprofitable plans and counties Remains confident

      4/30/25 6:00:00 AM ET
      $HUM
      Medical Specialities
      Health Care

    $EVH
    $HIMS
    $HUM
    Leadership Updates

    Live Leadership Updates

    See more
    • Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

      Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

      5/8/25 6:50:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer

      Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Nader Kabbani as Chief Operations Officer.1 A seasoned executive known for scaling trusted consumer and healthcare logistics businesses, Kabbani will oversee operations as the company expands access to personalized care for millions more individuals. This press release features multimedia. View the full release here: https://www.businesswire.com/ne

      5/5/25 9:01:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

      Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

      3/18/25 4:47:00 PM ET
      $CMBM
      $DOMO
      $EVH
      $MDRX
      Radio And Television Broadcasting And Communications Equipment
      Technology
      Computer Software: Prepackaged Software
      Other Consumer Services

    $EVH
    $HIMS
    $HUM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Humana upgraded by Raymond James with a new price target

      Raymond James upgraded Humana from Mkt Perform to Outperform and set a new price target of $315.00

      5/1/25 7:42:13 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Hims & Hers Health downgraded by TD Cowen with a new price target

      TD Cowen downgraded Hims & Hers Health from Buy to Hold and set a new price target of $30.00

      4/29/25 8:05:51 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Hims & Hers Health from Overweight to Equal-Weight and set a new price target of $60.00 from $42.00 previously

      2/18/25 7:09:28 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $EVH
    $HIMS
    $HUM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CenterWell Specialty Pharmacy Takes National Patient Choice Award

      Organization Recognized for Seventh Time in Eight Years CenterWell Specialty Pharmacy has once again received the MMIT Specialty Pharmacy Patient Choice Award in the PBM/Payer category, its seventh such win in the past eight years. The award recognizes best-in-class customer satisfaction and commitment to patient care by a specialty pharmacy. "There's something so rewarding about seeing our team's dedication to excellent care and support being recognized year after year by the people we serve," said Guillermo Sollberger, senior vice president of CenterWell Specialty Pharmacy and CenterWell Pharmacy. "We know that many of the patients who require specialty drugs are feeling overwhelmed, so

      5/13/25 9:00:00 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

      Proceeds intended to support Hims & Hers' global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising demand for high-quality, personalized care Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased

      5/8/25 10:25:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Evolent Announces First Quarter 2025 Results

      WASHINGTON, May 8, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent Health kicked off 2025 with first quarter results at the high end of our expectations, and we are reiterating our outlook for full year 2025 revenue and Adjusted EBITDA. We continue to see a very strong selling environment and we achieved significant organic growth with five

      5/8/25 4:10:00 PM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary

    $EVH
    $HIMS
    $HUM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Holder Diane bought $25,518 worth of shares (2,735 units at $9.33), increasing direct ownership by 4% to 70,584 units (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      3/10/25 8:20:54 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • PRESIDENT Mccarthy Daniel Joseph bought $99,470 worth of shares (11,040 units at $9.01), increasing direct ownership by 3% to 389,004 units (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      3/10/25 8:18:12 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Director Jelinek Richard M bought $273,750 worth of shares (30,000 units at $9.12) (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      3/10/25 8:16:20 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary

    $EVH
    $HIMS
    $HUM
    SEC Filings

    See more

    $EVH
    $HIMS
    $HUM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $EVH
    $HIMS
    $HUM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

      8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/13/25 5:23:44 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health Inc. filed SEC Form 8-K: Other Events

      8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/9/25 7:00:17 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Evolent Health Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Evolent Health, Inc. (0001628908) (Filer)

      5/8/25 4:12:58 PM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/12/24 3:52:47 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

      SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

      11/12/24 9:55:15 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/4/24 1:33:02 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Chief Operating Officer Baird Melissa exercised 33,333 shares at a strike of $2.43 and sold $1,867,376 worth of shares (33,333 units at $56.02) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/13/25 5:07:27 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Chief Legal Officer Boughton Soleil sold $181,160 worth of shares (3,235 units at $56.00), decreasing direct ownership by 2% to 156,427 units (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/13/25 5:07:16 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Chief Legal Officer Boughton Soleil sold $97,695 worth of shares (3,236 units at $30.19), decreasing direct ownership by 2% to 159,662 units (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      4/30/25 6:01:31 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care